Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Melanoma × enfortumab vedotin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Transitional Cell 8 Urinary Bladder Neoplasms 4 Ureteral Neoplasms 3 Neoplasm Metastasis 2 Metastatic Urothelial Cancer 2 Urologic Neoplasms 1 Urethral Neoplasms 1 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Salivary Gland Neoplasms 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Penile Squamous Cell Carcinoma (PSCC) 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Muscle-invasive Bladder Cancer 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Metastatic Castration-resistant Prostate Cancer 1 Melanoma 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Carcinoma, Adenoid Cystic 1 Breast Neoplasms 1

Interventions

Ipilimumab 93 Nivolumab 88 pembrolizumab 81 aldesleukin 65 Cyclophosphamide 42 Interleukin-2 39 trametinib 29 Temozolomide 28 Dacarbazine 28 fludarabine phosphate 27 dabrafenib 27 incomplete Freund's adjuvant 25 Vemurafenib 24 Bevacizumab 24 sargramostim 22 fludarabine 22 Radiosurgery 20 binimetinib 18 encorafenib 17 Paclitaxel 17 cobimetinib 15 Carboplatin 15 atezolizumab 14 Radiotherapy 14 Sorafenib 12 montanide ISA 51 11 CTLA-4 Antigen 11 Biopsy 11 talimogene laherparepvec 10 MART-1 Antigen 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06906822 2025-09-18

PlugIN

Grupo Español Multidisciplinar de Melanoma

Phase 2 Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡